Dnr/ref. LUP 2026-4

Annex 2 – Procurement specifications

Procurement: Actively managed biotechnology funds

Fondtorgsnämnden
Swedish Fund Selection Agency

Annex 2 – Procurement specifications

This annex summarises the procurement specifications that define the Fund Category being procured. The following items, with the exception of items 10 and 14, constitute mandatory requirements on the Fund and must be fulfilled as set out below.

	Item	**Description**	**Fulfilled as of (and thereafter during the contract period)**
1.	Investment strategy	Actively managed equity fund in the healthcare sector, primarily focused on large- and mid-cap biotechnology companies.	Closing date for tenders
2.	Fund type	UCITS The Fund must not be an exchange-traded fund (ETF) or part of a self-managing UCITS (i.e. a UCITS that has not appointed a management company, such as a self-managing SICAV or equivalent).	Closing date for tenders
3.	Feeder funds	Not permitted	Closing date for tenders
4.	Share class	Only accumulating share classes are permitted. The Fund must exist, and the offered unit class must have an ISIN code no later than the final bid submission date.	Closing date for tenders
5.	Trading currency	Any of the currencies approved for trading by the Swedish Pensions Agency, currently SEK, NOK, EUR and USD	Closing date for tenders
6.	Sustainability reporting	In accordance with SFDR article 8 or 9	Closing date for tenders
7.	Benchmark	Benchmark that is rules-based, transparent, constitutes an appropriate reference for the market it pertains to and is publicly disclosed in an appropriate manner.	Closing date for tenders

8.	Management activity rate	Minimum 2% active risk, relative to the Fund's benchmark or, if the Fund was established less than three years ago, active risk of the Strategy relative to the Fund's benchmark (based on a 3-year period, monthly data of closing prices, ex-post) or Minimum 60 % in active share relative to the Fund's benchmark (based on monthly data of closing prices) For the methods of calculating active risk and active share, see below.	Closing date for tenders
9.	FTN's category benchmark	Nasdaq Biotechnology Index	Date not applicable
10.	Leverage	Not permitted	During the contract period
11.	Investments in other funds	Not permitted	During the contract period
12.	Derivatives	Where derivatives are used, only standardised derivatives, including currency forwards (OTC), used for the purpose of managing transaction-related flows in the Fund, are allowed.	During the contract period
13.	Securities lending	Securities lending allowed, but not required.	Date not applicable
14.	Trading and NAV reporting	Daily trading and NAV reporting	During the contract period

Procedure for Determining the Fund's Investment strategy
To determine whether the Fund meets the Investment strategy, FTN will review the Fund's legal documents and the Investment strategy, specified therein. FTN will also use the Fund's benchmark index in this analysis.

In certain cases, for example where the Fund uses a standardised index, the Fund's holdings will be analysed, and FTN's category benchmark may serve as a reference point for the type of exposure expected in the Fund.

Methods of calculating

Active risk (Tracking error)
Active risk (Tracking error) is calculated as the ex-post volatility over a three-year period in relative monthly return between the portfolio and the Fund´s benchmark, scaled to yearly terms:

$$Active\ risk\ = \sqrt{12 * \frac{\sum_{i=1}^{N}\left(r_i^p - r_i^b - \bar{r}^{rel}\right)^2}{N-1}}$$

where r_i^p and r_i^b is the portfolio and the Fund´s benchmark return during month i and $\bar{r}^{rel}$ is the average relative return over the period N=36 months. The return of the portfolio should be calculated using market closing prices and from the formula it is given that sample standard deviation is assumed.

Active share
Active share is calculated by taking the absolute value of the difference in weight between the portfolio and the Fund´s benchmark for all assets, including cash holdings. These differences are summed up and divided by 2:

$$Active\ share\ = \frac{1}{2}\sum_{i=1}^{N}\left|w_i^p - w_i^b\right|$$

where w_i^p and w_i^b are the weights in the portfolio and the Fund´s benchmark of asset i and N is the union of all assets in the portfolio and the Fund´s benchmark. For derivatives the weight in the portfolio should be the underlying exposure. No substitution between assets with comparable exposure, such as shares in different share classes or depository receipts, should be done.